Master Clinical Trial Agreements
UT System Master CDAs
| Sponsor | Expiration Date |
|---|---|
| AbbVie, Inc. | 9/30/2023 |
| Amgen, Inc. | 4/22/2027 |
| AstraZeneca Pharmaceuticals, LP (Medimmune) | 2/27/2027 |
| Boehringer-Ingelheim | 11/1/2026 |
| Briston-Myers Squibb | 10/12/2025 |
| Citius | 6/18/2023 |
| Cytosorbents Corp. | 9/5/2023 |
| Genprex, Inc. | 6/1/2023 |
| Janssen Research & Development | 5/19/2026 |
| Novartis Pharmaceuticals Corp. | 1/13/2026 |
| PPD | 12/31/2022 |
| Regeneron | 5/18/2028 |
| Sanofi US Services, Inc. | 10/2024 |
UT System MCTAs
| Sponsor | Expiration Date |
|---|---|
| Abbott MCTA | 6/30/2025 |
| AbbVie, Inc. - Covers Allergan/Allergan Sales | 3/17/2027 |
| Amgen, Inc. | Not listed |
| Army Research Laboratory CRADA | 5/30/2024 |
| Astellas Pharma Global Development, Inc. | 10/17/2026 |
| AstraZeneca - Covers MedImmune, LLC | 3/16/2025 |
| Bristol-Myers Squibb (BMS) MCTA Investigator-Sponsored | 11/5/2028 |
| Bristol-Myers Squibb (BMS) MCTA Sponsor Initiated | 4/6/2026 |
| Genentech MCTA (Investigator Initiated) | 4/30/2028 |
| Genentech Sponsor Protocol Initiated MCTA | 1/15/2025 |
| Howmedica Osteonics Corp. (aka Stryker) | 7/25/2027 |
| Janssen MCTA - Covers Actelion Pharmaceuticals | 10/15/2025 |
| Lilly USA Sponsor Protocol Initiated MCTA | 12/5/2025 |
| Merck f/k/a Schering Corp. MCTA - Covers Acceleron | 6/15/2029 |
| Novartis Sponsor Protocol Initiated MCTA | 8/31/2023 |
| Pfizer Sponsor Protocol Initiated MCTA | 11/30/2025 |
| Pharmacyclics (acquired by Abbvie) MCTA | 1/10/2023 |
| Regeneron MCTA | 2/4/2024 |
| UCB Biosciences MCTA | 8/13/2027 |
UTSW Medical Center MCTAs
| Sponsor | Expiration Date |
|---|---|
|
Adaptive Biotechnologies |
12/17/2020 - Evergreen (automatically renews for twelve (12) months) |
|
Aimmune Therapeutics |
7/20/2022 – Evergreen (automatically renews for one (1) year term) |
|
Alexion Pharmaceuticals, Inc. - Registries Only |
9/27/2031 |
|
Alkermes, Inc. |
8/4/2029 |
|
Alpha Oncology |
Evergreen (automatically renews for one (1) year until notified) |
| Argos Therapeutics | No termination date listed |
|
Baxter Healthcare Corporation |
No termination date listed |
|
Bayer Healthcare Pharmaceuticals |
12/1/2024 |
|
Biogen MA Inc. |
10/9/2026 |
|
CARDIOMEMS |
No termination date listed |
|
Caris MPI, Inc., d/b/a Caris Life Sciences |
No termination date listed |
|
Celgene Corporation - Covers Juno Therapeutics |
9/30/2024 |
|
CHOP/COG with industry funding |
No termination date listed |
|
Edwards Lifesciences |
12/12/2027 |
|
Eisai Medical Research |
No termination date listed |
|
EMD Serono |
No termination date listed |
|
EMMES Company, LLC |
6/30/2026 |
|
Gilead FOCUS Agreement |
Master for various grant awards |
|
Hoosier Cancer Research Network |
Evergreen (automatically renews for one (1) year until otherwise) |
|
Insightec Ltd. |
3/23/2032 |
|
New England Research Institutes, Inc. (MCTA) |
06/30/2024 |
|
New England Research Institutes, Inc. (Amended MCTA) |
12/31/2024 |
|
Novo Nordisk |
01/18/2029 |
|
Philips Electronics North America Corporation |
8/3/2023 |
|
Precision Therapeutics Master Clinical Trial Agreement |
No termination date listed |
|
Public Health Institute (Industry Funded) |
No termination date listed |
|
Purdue Pharma L.P. Master Clinical Trial Agreement |
12/23/2023 |
|
Sanofi US Services Inc. Master Clinical Trial Agreement |
3/27/2029 |
| Sarepta Therapeutics, Inc. |
6/18/2025 |
|
Seagen Inc. |
3/23/2028 |
|
Siemens Medical Solutions USA, Inc. Master Research Agreement (May only be used for studies in which Parkland, UTSW, and Siemens are parties) |
11/18/2026 |
|
Sucampo Pharma Americas, LLC Master Clinical Trial Agreement |
No termination date listed |
|
Sunesis Pharmaceuticals |
No termination date listed |
|
Target PharmaSolutions |
7/31/2025 |
|
Verily Life Sciences, LLC |
01/06/2027 |